Literature DB >> 22653202

Can next-generation antibodies offset biosimilar competition?

Asher Mullard.   

Abstract

Mesh：

Substances：

Year:  2012        PMID： 22653202     DOI： 10.1038/nrd3749

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  8 in total

1.  Regulatory watch: Innovation in biologic new molecular entities: 1986-2014.

Authors:  Kathleen L Miller; Michael Lanthier
Journal:  Nat Rev Drug Discov       Date:  2015-02       Impact factor: 84.694

Review 2.  Access to cancer medications in low- and middle-income countries.

Authors:  Gilberto de Lima Lopes; Jonas A de Souza; Carlos Barrios
Journal:  Nat Rev Clin Oncol       Date:  2013-04-09       Impact factor: 66.675

Review 3.  Cost Effectiveness of Chemotherapeutic Agents and Targeted Biologics in Ovarian Cancer: A Systematic Review.

Authors:  Insiya B Poonawalla; Rohan C Parikh; Xianglin L Du; Helena M VonVille; David R Lairson
Journal:  Pharmacoeconomics       Date:  2015-11       Impact factor: 4.981

Review 4.  Etanercept biosimilars.

Authors:  Valderilio F Azevedo; Nathalia Galli; Alais Kleinfelder; Julia D'Ippolito; Paulo C M Urbano
Journal:  Rheumatol Int       Date:  2014-07-01       Impact factor: 2.631

5.  Towards controlling the glycoform: a model framework linking extracellular metabolites to antibody glycosylation.

Authors:  Philip M Jedrzejewski; Ioscani Jimenez del Val; Antony Constantinou; Anne Dell; Stuart M Haslam; Karen M Polizzi; Cleo Kontoravdi
Journal:  Int J Mol Sci       Date:  2014-03-14       Impact factor: 5.923

Review 6.  Biosimilars in dermatology.

Authors:  Małgorzata Mazur; Karolina Olek-Hrab; Jacek Karczewski; Ewa Teresiak-Mikołajczak; Zygmunt Adamski
Journal:  Postepy Dermatol Alergol       Date:  2015-10-29       Impact factor: 1.837

Review 7.  A multidisciplinary review of the policy, intellectual property rights, and international trade environment for access and affordability to essential cancer medications.

Authors:  Sangita M Baxi; Reed Beall; Joshua Yang; Tim K Mackey
Journal:  Global Health       Date:  2019-09-18       Impact factor: 4.185

8.  The cost-effectiveness of bevacizumab, ranibizumab and aflibercept for the treatment of age-related macular degeneration-A cost-effectiveness analysis from a societal perspective.

Authors:  Freekje van Asten; Charlotte T J Michels; Carel B Hoyng; Gert Jan van der Wilt; B Jeroen Klevering; Maroeska M Rovers; Janneke P C Grutters
Journal:  PLoS One       Date:  2018-05-17       Impact factor: 3.240
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.